PT  - JOURNAL ARTICLE
AU  - Graziani, Carlo
TI  - A Simplified Bayesian Analysis Method for Vaccine Efficacy
AID  - 10.1101/2020.12.07.20244954
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.07.20244954
4099  - http://medrxiv.org/content/early/2020/12/11/2020.12.07.20244954.short
4100  - http://medrxiv.org/content/early/2020/12/11/2020.12.07.20244954.full
AB  - We describe a simplified Bayesian analysis of vaccine trial data, in which a reparametrization of the Poisson likelihood leads to a factorization in which the protective vaccine efficacy VES and the nuisance parameter appear in different factors. As a consequence the posterior density acquires a factorized form, and marginalization over the nuisance parameter is trivial. Estimates of VES accordingly become a matter of simple manipulations of one-dimensional posterior probability densities. We demonstrate the method using the publically-released data on the efficacy of three vaccines agains SARS-CoV-2: the final Phase III data from the Pfizer/BioNTech and Moderna mRNA vaccines and the interim data released for the Sputnik V adenovirus-based vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis material is based upon work supported by the U.S. Department of Energy, Office of Science, under contract number DE-AC02-06CH11357.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data utilized in this manuscript is in the public domain. Hence no approval or exemption is required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data utilized in this manuscript has been publically released by the companies involved. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/